SNIDER LINDY enters NEXIEN BIOPHARMA, INC. with 440K shares plus derivative instruments
Holding both equity and derivatives at entry signals strong long-term conviction in the company.
Direct Derivatives
Filed: 6/13/2018ACC: 0001214659-18-004427
440K
Baseline shares
100% direct
440K
Direct ownership
1 position
80K
Derivative underlying
2 instruments
1
Security positions
All direct
Non-Derivative Holdings1
Common Stock
DirectShares owned440K
Total
440K direct440K
| Security Title | Shares Owned | Ownership Type |
|---|---|---|
| Common Stock | 440K | Direct |
| Total | 440K | 440K direct |
Derivative Holdings2
Class B Warrants (right to buy)
DirectUnderlying security
Common Stock
Underlying shares
40K
Shares owned
N/A
Exercise price
0.38
Expiration
—
Exercise window
—
Class C Warrants (right to buy)
DirectUnderlying security
Common Stock
Underlying shares
40K
Shares owned
N/A
Exercise price
0.50
Expiration
—
Exercise window
—
Total
Underlying
80K
Owned
0.00
| Security | Underlying | Exercise Price | Exercise Window | Expiration | Underlying Shares | Shares Owned |
|---|---|---|---|---|---|---|
| Class B Warrants (right to buy) Direct | Common Stock | 0.38 | — | — | 40K | N/A |
| Class C Warrants (right to buy) Direct | Common Stock | 0.50 | — | — | 40K | N/A |
| Total | 80K | 0.00 | ||||